NYSE · Biotech stocks database
BHVN (Biohaven Ltd. Common Shares) stock: $13.62, $2.06B market cap, $267.9M cash, $1.79B EV, $2.35B fully diluted market cap. Next expected readout: Oct-26. Lead program: BHV-1300 (Graves Disease), Phase 3. Data from Fully Diluted's biotech stocks database.
| Cash | $267.9M |
|---|---|
| Debt | $0.0M |
| Net cash | $267.9M |
| Enterprise value | $1,789.3M |
| Basic shares | 151.0M shares |
| Fully diluted shares | 172.8M shares |
| Fully diluted market cap | $2,353.8M |
| Cash per share | $1.77 |
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Loading BHVN daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Oct 13 - Nov 24 | Taldefgrobep Alfa | Phase 2 | Obesity; Overweight | — |
| Nov 12 - Dec 24 | BHV-7000 | Phase 2/3 | Focal Epilepsy | — |
| Dec 13, 2026 - Jan 24, 2027 | BHV-7000 | Phase 1 | Familial Erythromelalgia | — |
| Jan 12 - Feb 23 | BHV-7000 | Phase 2/3 | Focal Epilepsy | — |
| Jan 12 - Feb 23 | BHV-7000 | Phase 2 | Focal Epilepsy | — |
| Aug 12 - Sep 23 | BHV-1400 | Phase 1 | IgA Nephropathy | — |
| Sep 12 - Oct 24 | BHV-8000 10mg | Phase 2/3 | Parkinson Disease | — |
| Oct 13 - Nov 24 | BHV-1300 | Phase 1 | Graves Disease | — |
| Feb 12 - Mar 25 | BHV-1300 | Phase 3 | Graves Disease | — |
| Mar 14 - Apr 25 | BHV-1510 | Phase 1/2 | Solid Tumor | — |
| Jul 13 - Aug 24 | Temozolomide | Phase 2/3 | Glioblastoma | — |
| Oct 13 - Nov 24 | BHV-1400 | Phase 3 | IgA Nephropathy | — |
| Apr 12 - May 24 | BHV-1530 | Phase 1 | Solid Tumor | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.